NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Well, I did state, "Of course, all of this remains speculation." But I don’t believe this is an "insane leap". King Charles was diagnosed with cancer in 2024, yet prior to this:

-- NWBO submitted its MAA to the MHRA in December 2023.
-- NYAS and JAMA Oncology had already peer-reviewed the Phase III trial data.
-- The NHS likely monitored emerging clinical data, especially for treatments addressing serious unmet needs like glioblastoma and cancer.
-- NWBO treated patients via compassionate use cases, meaning the NHS would have had direct exposure to real-world efficacy data well before the MAA submission.

Additionally, it’s reasonable to believe early engagements between NWBO and NICE took place, allowing the NHS access to DCVax-L’s efficacy data well in advance of NWBO’s formal MAA submission. Why? Because in December 2022—two years BEFORE King Charles’s diagnosis—NICE began its appraisal of DCVax-L for glioblastoma.

Given all this, I can’t definitively say King Charles influenced NHS’s decision to place DCVax-L on the HCD list, nor can I assess the probability of it. But I can say, with confidence, that it remains a possibility—one rooted in reasonable speculation rather than baseless conjecture.